ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
SM62
|
53 |
15K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
53
|
15K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Establishes Strategic Partnership in South-East Asia
|
|
SM62
|
51 |
15K |
11 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
51
|
15K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion
|
|
SM62
|
34 |
13K |
2 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
34
|
13K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion
|
|
SM62
|
34 |
13K |
4 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
34
|
13K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion
|
|
SM62
|
34 |
13K |
9 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
34
|
13K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
|
|
SM62
|
32 |
11K |
8 |
15/12/23 |
15/12/23 |
ASX - By Stock
|
32
|
11K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Acurx Pharmaceuticals
|
|
SM62
|
28 |
9.7K |
2 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
28
|
9.7K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
|
|
SM62
|
13 |
3.8K |
6 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
13
|
3.8K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SM62
|
10 |
4.5K |
9 |
20/10/23 |
20/10/23 |
ASX - By Stock
|
10
|
4.5K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SM62
|
10 |
5.3K |
7 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
10
|
5.3K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SM62
|
10 |
5.3K |
5 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
10
|
5.3K
|
5
|
|